Sionna Therapeutics (NASDAQ:SION) Director Sells $5,270,902.00 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 115,844 shares of the company’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $45.50, for a total transaction of $5,270,902.00. Following the completion of the transaction, the director owned 2,555,877 shares in the company, valued at approximately $116,292,403.50. This trade represents a 4.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sionna Therapeutics Trading Up 5.6%

SION stock traded up $2.35 during mid-day trading on Thursday, hitting $43.99. 328,677 shares of the company were exchanged, compared to its average volume of 364,115. The business has a 50 day simple moving average of $39.79 and a 200-day simple moving average of $39.49. The stock has a market capitalization of $1.99 billion, a PE ratio of -22.79 and a beta of 1.33. Sionna Therapeutics, Inc. has a 1-year low of $16.38 and a 1-year high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). Equities research analysts expect that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Institutional Trading of Sionna Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Eventide Asset Management LLC acquired a new stake in shares of Sionna Therapeutics during the 4th quarter worth $26,290,000. Vanguard Group Inc. increased its position in shares of Sionna Therapeutics by 81.4% in the third quarter. Vanguard Group Inc. now owns 1,143,154 shares of the company’s stock worth $33,620,000 after purchasing an additional 512,803 shares during the period. State Street Corp raised its stake in Sionna Therapeutics by 188.7% in the fourth quarter. State Street Corp now owns 693,395 shares of the company’s stock valued at $28,526,000 after purchasing an additional 453,196 shares in the last quarter. Jennison Associates LLC raised its stake in Sionna Therapeutics by 30.1% in the first quarter. Jennison Associates LLC now owns 1,451,220 shares of the company’s stock valued at $58,179,000 after purchasing an additional 335,942 shares in the last quarter. Finally, Viking Global Investors LP lifted its position in Sionna Therapeutics by 8.2% during the second quarter. Viking Global Investors LP now owns 3,195,181 shares of the company’s stock worth $55,436,000 after purchasing an additional 242,427 shares during the period.

Analyst Upgrades and Downgrades

SION has been the subject of several recent research reports. Stifel Nicolaus boosted their price target on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, May 18th. JonesTrading lifted their target price on Sionna Therapeutics from $52.00 to $63.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. Wedbush started coverage on shares of Sionna Therapeutics in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $53.00 target price for the company. Citizens Jmp reissued a “market outperform” rating and issued a $63.00 target price on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Sionna Therapeutics in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Sionna Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $53.22.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.